Germany to end free pricing for patented medicines
This article was originally published in Scrip
Executive Summary
Germany's health ministry is planning to introduce compulsory price negotiations for patented drugs between the pharmaceutical industry and health insurers, it confirmed to Scrip. The measure could eventually put an end to free pricing in Europe's largest pharmaceutical market.